Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Dextromethorphan

Checked
From Pharmacopedia
Dissociative
Dextromethorphan
DXM

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions6 edges
Pharmacokinetic mechanismSubstrate / metabolism relationships from primary literature
Enzyme:CYP2D6 substrate major Primary 80 / 100
FDA Drug Interactions Table: sensitive index substrate of CYP2D6.
Inferred from pharmacokinetic dataMaterialised by the inference engine; provenance shown per row
Quinidine pk raises via CYP2D6 Inferred 76 / 100
Quinidine inhibits CYP2D6 (inhibitor_strong, intensity 95); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure raised)
Fluoxetine pk raises via CYP2D6 Inferred 72 / 100
Fluoxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure raised)
Paroxetine pk raises via CYP2D6 Inferred 72 / 100
Paroxetine inhibits CYP2D6 (inhibitor_strong, intensity 90); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
mechanism-based, interaction persists ~4-6 weeks after stopping the inhibitor
Inferred via Enzyme:CYP2D6 (exposure raised)
Bupropion pk raises via CYP2D6 Inferred 68 / 100
Bupropion inhibits CYP2D6 (inhibitor_strong, intensity 85); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure raised)
Mirabegron pk raises via CYP2D6 Inferred 44 / 100
Mirabegron inhibits CYP2D6 (inhibitor_moderate, intensity 55); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
Inferred via Enzyme:CYP2D6 (exposure raised)

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
Dissociative
Common uses
Pharmacy
Pharmacology
Purported mechanism
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor